ADI-925 / Adicet Bio - LARVOL DELTA

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates (Businesswire) - "Adicet has reprioritized its preclinical pipeline to focus on the development of ADI-270 as its lead preclinical candidate for renal cell carcinoma, with potential in other solid tumor indications. The Company has completed a pre-IND meeting for ADI-270 with the U.S. Food and Drug Administration and received positive feedback to support an IND filing in the first half of 2024....The Company expects to file an IND application for ADI-270 in the first half of 2024. Adicet has paused preclinical development of ADI-925 to prioritize corporate resources on IND-enabling activities for ADI-270."

Discontinued • FDA event • IND • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

ADI-925: an allogeneic off-the-shelf chimeric adapter (CAd) γδ T cell therapy targeting NKG2D ligand-expressing cancers (SITC 2023) - "A clinically suitable manufacturing process has been developed and generates cells that maintain potent tumor targeting. These data support continued development and further investigation of ADI-925 in the clinic."

Hematological Malignancies • Oncology • NKG2D

Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (Businesswire) - "Adicet Bio, Inc...announced the acceptance of three abstracts for a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held in San Diego, CA from November 1-5, 2023."

Clinical • Hematological Malignancies • Oncology • Solid Tumor

Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates (Businesswire) - "...'We expect to file an IND for ADI-270 in the first half of 2024, following our IND for ADI-925 in the second half of 2023'."

IND • Oncology

Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress (Businesswire) - "'Following the Phase 1 clinical update in December evaluating ADI-001 for relapsed or refractory non-Hodgkin’s lymphoma, we are continuing to track and enroll patients in the study and expect to report additional efficacy, durability, and safety data in the second quarter of 2023'....In the second quarter of 2023, Adicet plans to discuss the design of its first potential pivotal clinical study evaluating ADI-001 in post CAR T LBCL patients with the U.S. Food and Drug Administration (FDA), and initiate the study in the second half of the year, potentially in the third quarter....Adicet expects to submit an Investigational New Drug Application (IND) to the FDA for its lead preclinical candidate, ADI-925, in the second half of 2023."

Clinical protocol • IND • New trial • P1 data • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Businesswire) - "ADI-925, a novel engineered chimeric adaptor (CAd) gamma delta T cell product candidate, is engineered to provide broad antitumor activity in multiple heme and solid malignancies; IND submission expected second half of 2023; Four differentiated chimeric antigen receptor (CAR) and CAd programs targeting several hematologic and solid malignancies featured at SITC; Company to unveil new details from pipeline during R&D webcast event Thursday, November 10, 2022 at 9:00 a.m. ET....Adicet Bio, Inc..announced that positive preclinical data from four new pipeline programs will be featured at poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on November 10-11, 2022."

IND • Pipeline update • Preclinical • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor